
IMMP • NASDAQ
Unlock comprehensive alternative data signals to make better investment decisions

Track website visits, page views, unique visitors, and engagement metrics over time to gauge online interest and brand strength.

Monitor Twitter follower growth, engagement rates, and social media presence to understand brand reach and community sentiment.

Analyze TikTok follower trends and viral content performance to measure youth demographic appeal and cultural relevance.

Track Facebook page likes, comments, shares, and post engagement to assess community interaction and brand loyalty.

Monitor Instagram follower growth, engagement rates, and visual content performance across demographics.

Track YouTube channel growth, video views, and subscriber engagement to measure content marketing effectiveness.

Monitor LinkedIn company page followers and professional network growth to assess B2B brand strength and talent attraction.

Track open job positions and hiring trends as a leading indicator of company expansion, contraction, or strategic shifts.

Monitor employee headcount changes on LinkedIn to gauge organizational growth, restructuring, or cost-cutting measures.

Analyze sentiment scores from Reddit discussions to understand retail investor mood and potential price momentum.

Track daily news mentions across major publications to measure media attention, PR effectiveness, and market awareness.

View key financial metrics including Revenue, Net Income, EPS, Free Cash Flow, EBITDA, and Total Assets. Access 2-year quarterly charts for Revenue & Income and Free Cash Flow trends.

Analyze technical indicators including 50-day Simple Moving Average (SMA) with price overlay and Relative Strength Index (RSI) charts.
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
You don't hold IMMP in your mock portfolio yet.
Immutep is currently loss-making, as indicated by its negative EPS of -0.45 and a negative PE ratio of -6.56, which reflects the absence of positive earnings. These metrics suggest that the investment case is presently driven more by expectations of future clinical or commercial success than by current profitability. Without evidence of improving earnings trends, the financial profile remains fundamentally weak and high risk.
The stock has rallied sharply, rising 63.9% over the last month and now trades at $2.95, well above its 200-day moving average of $1.85, indicating a strong recent uptrend. However, the RSI at 32.45 is near oversold territory, suggesting recent selling pressure or consolidation after the run-up. Overall, price action reflects strong medium-term momentum but short-term caution as the stock digests gains.
Alternative data for Immutep shows modest and mostly flat engagement levels, with low but slowly rising social media followings and stagnant web traffic and hiring. Social channels like LinkedIn and YouTube are growing at low single-digit rates, suggesting incremental but not explosive investor or stakeholder interest. The absence of job growth and flat traffic point to a stable but not aggressively expanding operational footprint.
Immutep’s stock shows strong recent price momentum above its long-term average, but this is not yet supported by profitability or robust alternative data signals. The company remains fundamentally loss-making, and external engagement metrics are steady rather than rapidly improving. Overall, the setup appears balanced between upside optionality from recent price strength and downside risk from weak underlying earnings, leading to a neutral stance.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
Key moves vs recent baseline (last day / last week)
Plain-English summary of the biggest drivers (informational)
Potential risk factors to review
Based on earnings timing, volatility, liquidity and crowd activity. Informational signals only — not investment advice.
Reassess your thesis if any of these occur: